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Da Li1,2*, Fang-Fang Bi1, Ji-Min Cao3, Chen Cao4, Bo Liu5 and Qing Yang1*Abstract
Background: DNA methyltransferase 1 (DNMT1) plays a critical role in breast cancer progression. However, the
epigenetic mechanism regulating DNMT1 expression remains largely unknown.
Methods: Epigenetic regulation of DNMT1 was assessed in 85 invasive ductal carcinomas from BRCA1 mutation
carriers. Association between clinicopathological features and DNMT1 promoter methylation was determined using
Fisher’s exact test. Univariate analysis of survival was performed using the Kaplan-Meier method. Multivariate Cox
regression analysis was performed to identify the independent prognostic factors for overall survival.
Results: Hypermethylated E2F transcription factor 1 (E2F1) motif is a key regulatory element for the DNMT1 gene in
BRCA1-mutated breast cancer. Mechanistically, the abnormal E2F1 motif methylation-mediated loss of active histone
H3 lysine 9 acetylation (H3K9ac) and transcription factor E2F1 enrichment synergistically inhibited the transcription
of DNMT1. Clinicopathological data indicated that the hypermethylated E2F1 motif was associated with histological
grade, lymph node, Ki67 and E-cadherin status; univariate survival and multivariate analyses demonstrated that
lymph node metastasis was an independent and reliable prognostic factor for BRCA1-mutated breast cancer
patients.
Conclusions: Our findings imply that genetic (such as BRCA1 mutation) and epigenetic mechanisms (such as DNA
methylation, histone modification, transcription factor binding) are jointly involved in the malignant progression of
DNMT1-related breast cancer.
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Breast cancer is the most prevalent malignancy, and is a
leading cause of mortality in women worldwide [1]. Ac-
cumulating evidence indicates that hereditary factors
and epigenetic events are implicated in the initiation and
progression of breast cancer and resistance to endocrine
therapies [2]. To date, BRCA mutations are the only
known cause of hereditary breast cancer [3], and DNA* Correspondence: leeda@ymail.com; yangq@sj-hospital.org
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stated.methylation is among the most well-studied epigenetic
modifications, which is maintained by the enzyme DNA
methyltransferase 1 (DNMT1) [4]. The growing body of
research suggests that DNMT1 plays an important role
in the development of breast cancer [5-12]. However, ex-
pression levels of DNMT1 in breast cancer tissues have
been a matter of debate [5,6,8,10,12], and the underlying
mechanism is still not entirely clear. In mammals, pro-
moter methylation at CpG dinucleotides is an important
feature regulating gene expression [13]. Therefore, the
present study was undertaken to investigate the DNA
methylation patterns in the core promoter region of
DNMT1 in human breast cancers with identified BRCA1
mutations compared to those without, and to providehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lation of DNMT1 expression.
Results
BRCA1-mutated breast cancer displayed a
hypermethylated E2F1 motif and promoter region
To investigate DNMT1 transcriptional regulation through
epigenetic mechanisms, we assessed the DNA methylation
status of the DNMT1 core promoter region (from −99
to +521, with +1 denoting the transcription initiation site) in
BRCA1-mutated and non-mutated breast cancer, and their
adjacent normal breast tissues. As shown in Figure 1Aiii
and 1B, BRCA1-mutated breast cancer exhibited global
promoter hypermethylation (P= 0.044; Figure 1D), espe-
cially around the E2F1 motif (P= 0.017; Figure 1C).
No similar changes were observed in non-BRCA1-mutated
breast cancer (Figure 1Aii).
Low DNMT1 transcript levels showed a significant inverse
correlation with hypermethylated E2F1 motif in
BRCA1-mutated breast cancer
Real-time PCR and immunohistochemical analysis showed
that the levels of DNMT1 mRNA and protein were de-
creased in BRCA1-mutated breast cancer, compared to
adjacent normal breast tissues (P < 0.05; Figure 2C and D),
DNMT1 protein levels was further confirmed by western
blotting [see Additional file 1]. Although there was no sig-
nificant difference in mRNA levels between non-BRCA1-
mutated breast cancer and adjacent normal breast tissues
(Figure 2A, P = 0.513), the protein expression of DNMT1
was upregulated (P < 0.05; Figure 2B). In addition, we ana-
lyzed the correlation between DNMT1-positive cells or
mRNA levels and the number of methylated sites within
the E2F1 motif (+182) or DNMT1 core promoter region
(−99 to +521) in BRCA1-mutated breast cancer and adja-
cent normal breast tissue (Figure 2Ei-Eiv). It is, however,
interesting to note that only a significant inverse cor-
relation was observed between DNMT1 mRNA levels
and the methylated E2F1 motif (R = 0.755, P < 0.001;
Figure 2Eiv).
Hypermethylated E2F1 motif is a key regulatory
mechanism for DNMT1 transcription in BRCA1-mutated
breast cancer
Based on the results above, we next explored the relation-
ship between E2F1 motif methylation and DNMT1 ex-
pression in a large number of BRCA1-mutated breast
cancer specimens. Similar results were observed using
methylation-specific PCR (Figure 3Ai), and BRCA1-
mutated cancer specimens were classified into unmethy-
lated and methylated groups for comparison of the protein
expression of DNMT1. The methylated group showed sig-
nificantly lower expression of DNMT1 in comparison to
the unmethylated group (P = 0.0167; Figure 3Aii). Tofurther confirm the role of cytosine located in the E2F1
motif, a point mutation of cytosine to thymine was
inserted in the E2F1 element (Figure 3Bi). Then, the con-
sensus E2F1 (con.E2F1) and mutated E2F1 (mut.E2F1)
were transiently transfected into 293 T cells, and primary
non-mutated and BRCA1-mutated breast cancer and their
corresponding normal breast cells. Notably, only in
BRCA1-mutated breast cancer cells was the E2F1 motif
found to be the critical element for DNMT1 transcription
(Figure 3Bii).
Recently, a substantial body of evidence has been re-
ported which suggests that most of the known genes
contain specific motifs, such as G-quadruplex in their pro-
moter regions, which can modulate gene transcription by
affecting the binding of histones [14]. Therefore, the CD
spectra were used to gain information on whether the
methylated E2F1 motif can influence the structure of the
DNMT1 promoter. However, our results showed that the
methylation of cytosine located in a CpG within the E2F1
motif may not affect the structure of DNMT1 (Figure 3C).
Loss of H3K9ac and E2F1 enrichment around the
hypermethylated E2F1 motif in BRCA1-mutated breast
cancer
To obtain further understanding of the regulatory po-
tential of the crosstalk between DNA methylation and
histone modification in controlling DNMT1 transcrip-
tion, we examined the active histone markers H3K9ac,
H3K18ac, H3K27ac, H3K4me1, H3K4me2, H3K4me3,
H3K36me3 and H3K79me, and the repressive histone
markers H3K9me, H3K9me2, H3K9me3, H3K27me,
H3K27me2 and H3K27me3 in the core promoter of
DNMT1, especially around the E2F1 motif; we also fo-
cused on the enrichment of the transcription factor
E2F1, due to the fact that the hypermethylated E2F1
motif was observed in BRCA1-mutated breast cancer
(Figure 1Aiii). Chromatin immunoprecipitation analysis
indicated that the levels of H3K9ac and E2F1 around the
E2F1 motif were only significantly decreased in BRCA1-
mutated breast cancer (Figure 4A and B). These results,
together with the methylation data in Figures 1, 2 and 3,
suggest that DNMT1 transcription is associated with
changes in epigenetic features, including decreased
H3K9ac and E2F1 enrichment, and the hypermethylated
E2F1 motif. However, no differences exist in histone
markers around the E2F1 motif between normal and can-
cer tissues in BRCA1 wild type cases [see Additional file 2].
H3K9ac and E2F1 present in the E2F1 motif are
responsible for the transcriptional regulation of DNMT1
in BRCA1-mutated breast cancer
As described previously by Jin [15], we observed that
only the combined knockdown of GCN5 and PCAF can
specifically induce a decrease of H3K9ac around the
250 bases
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Figure 1 Methylation patterns of the DNMT1 promoter in BRCA1-mutated and non-mutated breast cancer. Ai, location of CpG sites in
the core promoter region of DNMT1. Genomic coordinates are shown, along with the primer-amplified fragments, GC percentage, location of
individual CpG dinucleotides (dashes), the DNMT1 RefSeq gene (exon 1 shown as a blue box and intron shown as an arrowed line), and CpG
island (green bar). The arrow indicates the direction of transcription. Aii and Aiii, comparative analysis of methylation patterns in the core promoter
region of DNMT1 in non-mutated and BRCA1-mutated breast cancer, and their adjacent normal breast tissues (each group, n = 15). The circles
correspond to the CpG sites denoted by black dashes in Figure 1Ai. Closed circles, methylation; open circles, unmethylated. Ten individual clones were
sequenced for each sample. Arrow shows the methylation of a cytosine located in a CpG within the E2F1 motif (position +182, +1 is the transcription
initiation site). B, summary of the methylation patterns of DNMT1 core promoter in BRCA1-mutated breast cancer and adjacent normal breast tissues.
The y-axis shows the mean methylation sites. C and D, overall methylation percentage of the E2F1 motif and the DNMT1 core promoter region
(−99 to +521) from BRCA1-mutated breast cancer and adjacent normal breast tissues. Bar graphs show mean ± SD.
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http://www.molecular-cancer.com/content/13/1/26E2F1 motif (Figure 5Ci). Interestingly, knockdown of
E2F1 showed a similar effect to knockdown of GCN5
and PCAF (Figure 5Ci); therefore, an alternative pos-
sibility may be that E2F1 can recruit GCN5 and PCAFto the E2F1 motif, which was confirmed by co-
immunoprecipitation analysis (Figure 5D). As shown in
Figure 5Cii, knockdown of E2F1 was an effective way to






















































































































































lsCancer  R = 0.052  P = 0.855
Control  R = 0.468  P = 0.079
Cancer  R = 0.428  P = 0.111
Control  R = 0.467  P = 0.079
Cancer  R = 0.755  P  0.001
Control  R = 0.181  P = 0.519
Cancer  R = 0.032  P = 0.916
Control  R = 0.137  P = 0.626
Ei Eii Eiii Eiv
BRCA1 mutation
Non-BRCA1 mutation
Figure 2 Expression patterns of DNMT1 in BRCA1-mutated and non-mutated breast cancer. A and C, relative DNMT1 mRNA levels were
measured in non-mutated and BRCA1-mutated breast cancer, and their adjacent normal breast tissues. Bi and Di, sections were subjected to
immunostaining for DNMT1 in non-mutated and BRCA1-mutated breast cancer, and their adjacent normal breast tissues. Arrow shows positive
staining for DNMT1 in the nuclei. Bii and Dii, summary of the percentages of DNMT1-positive cells from the measurements shown in Bi and Di,
respectively. Magnification is 400×. Ei and Eii, correlation between the DNMT1-positive cells and methylated sites (+182) or (−99 to +521) in
BRCA1-mutated breast cancer and adjacent normal breast tissues. Eiii and Eiv, correlation between the relative DNMT1 mRNA levels and
methylated sites (+182) or (−99 to +521) in BRCA1-mutated breast cancer and adjacent normal breast tissues. Open circles, normal breast tissues;
closed circles, breast cancer tissues (each group n = 15).
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http://www.molecular-cancer.com/content/13/1/26of H3K9ac around the E2F1 motif. Meanwhile, we ob-
served that knockdown of GCN5, PCAF and E2F1 had
no detectable effect on the cell morphology and prolifer-
ation (Figure 5A and B). Of particular note, as described
in Figure 4, the hypermethylated E2F1 motif of theDNMT1 promoter was accompanied by loss of H3K9ac
and E2F1 enrichment in BRCA1-mutated breast cancer.
After the deletion of H3K9ac and/or E2F1 enrichment in
BRCA1-mutated breast cancer, the transcription of
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Figure 3 Repression of DNMT1 promoter activity by methylated E2F1 motif. Ai, comparative analysis of E2F1 motif methylation between
BRCA1-mutated breast cancer and adjacent normal breast tissues. Aii, relationship between DNMT1 protein expression and promoter methylation in
BRCA1-mutated breast cancer and adjacent normal breast tissues (U; unmethylated group, n = 46, M; methylated group, n = 39). Bi, the schematic
shows that the nucleotide sequence of consensus E2F1 motif (Con.E2F1) was point mutated at position +182 (C to T) to generate the Mut.E2F1.
Bii, 293 T cells, and 15 primary non-mutated and BRCA1-mutated breast cancer and their normal breast cells were transfected with Con.E2F1 and Mut.
E2F1. 24 hours after transfection, whole-cell extracts were analyzed for luciferase activity. Each experiment was repeated four times for 293 T cells and
primary breast cells of each patient. Bar graphs show mean ± SD. Ci, the schematic represents the selected nucleotide sequence containing the E2F1
motif, with or without a methyl group at the fifth position of the cytosine pyrimidine ring at position +182. Cii and Ciii, The CD spectra of the selected
nucleotide sequence in the presence of 100 mM Na+ or 100 mM K+ are shown.
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clinicopathological characteristics in BRCA1-mutated
breast cancer
The correlation between E2F1 motif methylation and cli-
nicopathological parameters was analyzed using Fisher s
exact test. As shown in Table 1, E2F1 motif methylationwas associated with histological grade (P = 0.006), lymph
node (P = 0.014), Ki67 (P = 0.030) and E-cadherin status
(P = 0.030). No significant associations were observed bet-
ween methylation of the E2F1 motif and age at diagnosis,
menstrual status, tumor size, estrogen receptor, proges-






























































































































































Figure 4 Comparative analysis of histone modification and E2F1 enrichment around the E2F1 motif between BRCA1-mutated breast
cancer and adjacent normal breast tissues. A, chromatin immunoprecipitation was performed using antibodies to H3K9Ac, H3K18Ac, H3K27Ac,
H3K4me1, H3K4me2, H3K4me3, H3K36me3, H3K79me, H3K9me, H3K9me2, H3K9me3, H3K27me, H3K27me2, H3K27me3 and E2F1. PCR was
performed for regions within the CpG islands and around the E2F1 motif. A negative control without antibodies is included for comparison.
B, representative results of 15 primary BRCA1-mutated breast cancer and their normal breast tissues are shown. Bar graphs show mean ± SD.
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patients with BRCA1-mutated breast cancer
We analyzed the overall survival to assess the prognostic
significance. Multivariate Cox regression analysis indicated
that lymph node metastasis was an independent prognos-
tic factor for predicting the overall survival of BRCA1-
mutated breast cancer patients (Table 2, P = 0.038). We
also performed Kaplan-Meier analysis and log-rank tests
for overall survival to define prognostic subgroups. The
results revealed that the significant prognostic factors were
histological grade (Figure 6D, P = 0.004), lymph node
metastasis (Figure 6E, P = 0.004), E-cadherin (Figure 6K,
P = 0.015) and DNMT1 methylation (Figure 6L, P = 0.016).
Moreover, patients with premenopausal (Figure 6B,
P = 0.155), estrogen receptor-negative (Figure 6F, P = 0.170)
and p53-negative (Figure 6I, P = 0.089) breast cancer
showed a trend for poor overall survival, although this was
not statistically significant. No significant difference in
overall survival was found among patients with different
ages at diagnosis, tumor size, progesterone receptor status,
c-erbB-2 status or Ki67 status (Figure 6A, C, G, H and J).
Discussion
Promoter methylation, with concurrent changes in his-
tone modifications, is an epigenetic phenomenon whichcan affect the conformation of chromatin and the accessi-
bility of DNA for transcription factors [13,16]. E2F1 is an
important transcription factor and has a highly conserved
DNA-binding domain that recognizes a common se-
quence motif (5′-TTTC[CG]CGC-3′) which is located
within the DNMT1 promoter [17]. In this study, we report
for the first time that (i) BRCA1-mutated breast cancer
displayed a hypermethylated E2F1 motif and promoter re-
gion; (ii) the hypermethylated E2F1 motif was negatively
correlated with DNMT1 mRNA levels; and (iii) E2F1 is a
key transcriptional regulator of DNMT1. The molecular
mechanism may involve hypermethylated E2F1 motif-
mediated loss of histone modification H3K9ac and tran-
scription factor E2F1 enrichment synergistically inhibiting
the transcription of DNMT1. In addition, Additional file 3
showed that no correlation was observed between DNMT1
mRNA or methylated CpG motifs, and H3K9ac or E2F1
enrichment. As shown in Additional file 4, BRCA1 status
may also not affect H3K9ac and E2F1 enrichment around
the E2F1 motif. These results suggest that abnormal me-
thylation of the E2F1 motif is the initial factor. Interes-
tingly, the synergistic inhibitory effects of hypermethylated
E2F1 motif, histone modification H3K9ac and transcription
factor E2F1 were primarily observed in cells originating
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Figure 5 (See legend on next page.)
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Figure 5 H3K9ac and E2F1-mediated transcriptional regulation of DNMT1. Ai, RT-PCR showing GCN5, PCAF and E2F1 levels before and after
knockdown by shRNAs, and normalized to β-actin expression. Aii, the results from three independent experiments are represented as mean ± SD.
Bi, EdU labeling showing proliferation of GCN5, PCAF and E2F1-silenced and control cells. Blue, Hoechst 33342 labeling of cell nuclei; Red, EdU
labeling of nuclei of proliferative cells. Bii, the EdU incorporation rate was expressed as the ratio of EdU positive cells to total Hoechst33342
positive cells. Ci and Cii, analysis of histone modification H3K9ac and transcription factor E2F1 enrichment around the E2F1 motif within the CpG
islands after the deletion of GCN5, PCAF or E2F1. D, The interaction of E2F1 and GCN5 or PCAF were examined by the immunoprecipitation of
cell extracts with an antibody to E2F1, and co-immunoprecipitation of E2F1, GCN5 and PCAF by western blot analysis. Results of Figure 5A-D were
obtained in BRCA1-mutated breast cancer cells, and the same results were also obtained in 293 T cells and non-BRCA1 mutated breast cancer
cells. Ei-Ev, the DNMT1 expression levels after deletion of H3K9ac and E2F1 around the E2F1 motif in 293 T cells, and 15 primary non-mutated
and BRCA1-mutated breast cancer and their normal breast cells. Each experiment was repeated four times for 293 T cells and primary breast cells
of each patient. Bar graphs show mean ± SD. * P < 0.05 vs. Control.
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tive to the loss of H3K9ac and E2F1 enrichment around
the E2F1 motif in the core promoter of DNMT1. Accor-
dingly, specific regulatory mechanisms may exist, and
DNMT1 expression is likely to be the result of a complex
interaction of multiple factors in BRCA1-mutated breast
cancer cells. This observation is consistent with previous
reports that E2F transcription factors may be key me-
diators regulating the expression of DNMT1 [17,18], and
that DNMT1 was a transcriptional target of BRCA1, as
BRCA1 deficiency was associated with decreased levels of
DNMT1 [19]. Notably, although the methylation patterns
and mRNA expression of DNMT1 showed no significant
change in non-BRCA1-mutated breast cancer, the protein
expression of DNMT1 is up-regulated. It appears that
post-translational modification might be an important
method for regulating DNMT1 expression and function.
Agoston suggested that the cause of the elevated DNMT1
protein levels could be attributed to an increase in protein
half-life in breast cancer [5]. As shown in Additional file 5,
global DNA hypomethylation was observed in BRCA1-
mutated breast cancer; therefore, it can be speculated that
abnormal E2F1 and H3K9ac mediated the decreased ex-
pression of DNMT1 might be responsible for the global
DNA hypomethylation. It is interesting to note that
DNMT1 can be recruited to the promoter of BRCA1,
locking in marked suppression of BRCA1 through pro-
moter methylation [20]. Therefore, these data suggest that
dynamic cross-talk between DNMT1 and BRCA1 exists in
BRCA1-mutated breast cancer.
Promoter hypermethylation is often associated with
adverse clinical factors [21]. In line with this, clinico-
pathological data indicated that the hypermethylated
E2F1 motif was significantly associated with histological
grade, lymph node, Ki67 and E-cadherin status in
BRCA1-mutated breast cancer (Table 1). Moreover, uni-
variate survival analysis demonstrated an association be-
tween the hypermethylated E2F1 motif and an increased
risk of death. Multivariate survival analysis indicated
that lymph node metastasis was an independent prog-
nostic factor for BRCA1-mutated breast cancer patients.
This study provides new insights into the causes andprognosis of DNMT1 inactivation in BRCA1-mutated
breast cancer.
Conclusions
Our study identified epigenetic-mediated DNMT1 tran-
scriptional repression, which involved the hypermethylated
E2F1 motif-mediated loss of active histone modification
H3K9ac and transcription factor E2F1 enrichment in
BRCA1-mutated breast cancer. These results will further
our understanding as to how the genetic (e.g., BRCA1 mu-
tation) and epigenetic mechanisms (e.g., DNA methy-
lation, histone modifications and transcription factor
binding) are jointly involved in the malignant progression
of DNMT1-related breast cancer.
Methods
Patients and tissue collection
This study was approved by the Institutional Review
Board at China Medical University. Eighty-five invasive
ductal carcinomas from BRCA1 mutation carriers and
fifteen invasive ductal carcinomas from non-BRCA1 mu-
tation carriers were enrolled between 2007 and 2009; all
patients gave informed consent. Fresh breast cancer and
adjacent normal breast tissues were obtained at the time
of primary surgery before any chemotherapy or radio-
therapy had been administered. Hematoxylin and eosin
staining of the samples for histopathological diagnosis
and grading were performed by three staff pathologists
using the Nottingham Combined Histologic Grade. The
tumor stages were classified according to the National
Comprehensive Cancer Network guidelines. All patients
were screened for BRCA1 mutations by multiplex poly-
merase chain reaction with complete sequence analysis
as previously reported [22-24]. Their characteristics are
given in Table 1.
Cell culture, lentiviral infection and cell proliferation assay
Detailed isolation and cultivation protocols were estab-
lished as previously described [25]; breast cancer and
normal cells were maintained in CnT-27 mammary epi-
thelium medium (CELLnTEC, Bern, Switzerland). Hu-
man 293 T cells were maintained in Dulbecco’s modified
Table 1 Association between DNMT1 promoter
methylation and clinicopathological features in
BRCA1-mutated breast cancer
n M (%) UM (%) P
Age at diagnosis 1.000
≤ 50 y 30 14 35.90 16 34.78
> 50 y 55 25 64.10 30 65.22
Menstrual status 0.282
Premenopausal 38 20 51.28 18 39.13
Postmenopausal 47 19 48.72 28 60.87
Tumor size 0.164
≤ 5 cm 59 24 61.54 35 76.09
> 5 cm 26 15 38.46 11 23.91
Histological grade 0.006
I-II 63 23 58.97 40 86.96
III 22 16 41.03 6 13.04
LN status 0.014
Positive 35 22 56.41 13 28.26
Negative 50 17 43.59 33 71.74
ER status 0.282
Positive 47 19 48.72 28 60.87
Negative 38 20 51.28 18 39.13
PR status 0.269
Positive 50 20 51.28 30 65.22
Negative 35 19 48.72 16 34.78
c-erbB-2 status 0.378
Positive 36 19 48.72 17 36.96
Negative 49 20 51.28 29 63.04
p53 status 0.258
Positive 30 11 28.21 19 41.30
Negative 55 28 71.79 27 58.70
Ki67 status 0.030
Positive 62 33 84.62 29 63.04
Negative 23 6 15.38 17 36.96
E-cadherin status 0.030
Positive 68 27 69.23 41 89.13
Negative 17 12 30.77 5 10.87
M, methylated; UM, unmethylated; LN, lymph node; ER, estrogen receptor;
PR, progesterone receptor.
Table 2 Prognostic factors for overall survival by
multivariate Cox regression analysis in BRCA1-mutated
breast cancer
Variable RR 95% CI P
Age at diagnosis (> 50 y vs ≤ 50 y) 1.059 0.982-1.143 0.137
Menstrual status (Post vs Pre) 0.258 0.043-1.542 0.138
Tumor size (> 5 cm vs≤ 5 cm) 0.389 0.107-1.413 0.151
Histological grade (III vs I-II) 2.628 0.642-10.761 0.179
LN status (Pos vs Neg) 3.511 1.074-11.481 0.038
ER status (Pos vs Neg) 0.561 0.123-2.554 0.455
PR status (Pos vs Neg) 1.558 0.420-5.775 0.507
c-erbB-2 status (Pos vs Neg) 1.429 0.422-4.832 0.566
p53 status (Pos vs Neg) 0.437 0.112-1.703 0.233
Ki67 status (Pos vs Neg) 0.628 0.120-3.271 0.580
E-cadherin status (Pos vs Neg) 0.651 0.158-2.678 0.552
DNMT1 methylation (M vs UM) 1.386 0.337-5.699 0.651
Post, postmenopausal; Pre, premenopausal; LN, lymph node; ER, estrogen
receptor; PR, progesterone receptor; Pos, positive; Neg, negative; M, methylated;
UM, unmethylated; RR, relative risk; CI, confidence interval.
Li et al. Molecular Cancer 2014, 13:26 Page 9 of 12
http://www.molecular-cancer.com/content/13/1/26Eagle’s medium with 10% fetal bovine serum (Invitrogen,
CA USA). Lentiviral vectors expressing short hairpin
RNAs (shRNA) against BRCA1 (NM_007299) were
obtained from Genechem Co., Ltd (Shanghai, China),
and synthesized as follows: Forward: 5-CCGGAACCTG
TCTCCACAAAGTGTGCTCGAGCACACTTTGTGGA
GACAGGTTTTTTTG, and Reverse: 5-AATTCAAAA
AAACCTGTCTCCACAAAGTGTGCTCGAGCACACT
TTGTGGAGACAGGTT. The non-silencing siRNAsequence (TTCTCCGAACGTGTCACGT) was used as a
negative control. For overexpression of BRCA1, the open
reading frame of BRCA1 (NM_007299) was cloned into
the lentiviral vector GV287 (Ubi-MCS-3FLAG-SV40-
EGFP) (GeneChem). The shRNA lentiviral particles of
GCN5 (sc-37946-V), PCAF (sc-36198-V) and E2F1
(sc-29297-V) were purchased from Santa Cruz Biotech-
nology (CA, USA). Transfections were performed using
the polybrene and enhanced infection solution (Gene-
chem) according to the manufacturer’s recommended
protocol, the knowdown effiency for the double-knockdown
and triple-knockdown were shown in Additional file 6. After
48 hours of infection, cell proliferation was determined
using the Cell-Light™ EdU Apollo®643 In Vitro Imaging Kit
(Ribobio, Guangzhou, China) following the instructions pro-
vided by the manufacturer.
DNA methylation analysis
Genomic DNA from the breast cancer and adjacent normal
breast tissues was extracted using a TIANamp Genomic
DNA kit (Tiangen Biotech, Beijing, China). Sodium bisulfite
conversion, polymerase chain reaction (PCR) amplification
and general experimental procedure were performed as
previously described [22]. The specific primer sequences
for bisulfite sequencing and methylation-specific PCR are
described in Additional file 7. Global DNA methylation was
measured as previously described [26].
Real-time PCR and immunohistochemistry analysis
Real-time PCR and immunohistochemistry were per-
formed as previously described [22]. The specific primer
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Figure 6 Kaplan-Meier analysis of overall survival for 85 BRCA1-mutated breast cancer patients. The following variables were analyzed:
age at diagnosis (A), menstruation (B), tumor size (C), grade (D), lymph node (E), ER (F), PR (G), c-erbB-2 (H), p53 (I), Ki67 (J), E-cadherin (K) and
DNMT1 methylation (L). Pre, premenopausal; Post, postmenopausal; ER, estrogen receptor; PR, progesterone receptor; Neg, negative; Pos, positive;
UM, unmethylated; M, methylated.
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http://www.molecular-cancer.com/content/13/1/26The primary antibody for immunohistochemistry was
rabbit anti-DNMT1 of human origin, and are listed in
Additional file 8 (1:200; Santa Cruz Biotechnology).
Chromatin immunoprecipitation (CHIP), site-directed
mutagenesis, transfection and dual-luciferase
reporter assay
CHIP, site-directed mutagenesis, transfection and dual-
luciferase reporter assays were performed as previously
described [27]. The specific primer sequences for site-
directed mutagenesis and CHIP are provided in Additional
file 7. The specific antibodies for CHIP are provided in
Additional file 8.
Co-immunoprecipitation (CO-IP) and immunoblotting
CO-IP was performed using an immunoprecipitation kit
(Invitrogen) according to the manufacturer’s recom-
mended protocol. Then, the cell lysates and immunopre-
cipitates were analyzed by immunoblotting. The specific
antibodies for CO-IP and immunoblotting are provided
in Additional file 8.
Circular dichroism (CD) spectra
The CD spectra were obtained on a Jasco J-810 spectropo-
larimeter at 25°C using a 0.1 cm path length cell; datawere collected with a 2 nm slit width from 350 to 200 nm
at 0.5 nm intervals and averaged over three scans. CD ex-
periments were carried out on DNA samples (5 μM) using
a buffer containing 0.2 M phosphate buffer (pH 7.0) in the
presence of 100 mM Na+ or K+. The DNA samples were
annealed by heating to 95°C for 5 min followed by cooling
to room temperature over 10 h before analysis. The DNA
sequence is as follows: 5-CCCCTCCCCATCGGTTTC“C
(CH3 or non-CH3)” GCGCGAAAAGCCGGGGCGCC,
and was synthesized by Sangon Biotech Ltd (Shanghai,
China).
Statistical analysis
Regression analysis was used to examine the possible rela-
tionship between DNMT1 mRNA or protein levels, and
the status of promoter methylation. The association bet-
ween clinicopathological features and DNMT1 promoter
methylation was determined using the Fisher’s exact test.
Univariate analysis of survival was performed using the
Kaplan-Meier method. Multivariate Cox regression ana-
lysis was performed to identify the independent prognos-
tic factors for overall survival. The data are presented as
means ± SD. Statistical differences in the data were eva-
luated by Student’s t test or one-way ANOVA as appro-
priate, and were considered significant at P < 0.05.
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Additional file 1: Expression levels of DNMT1 in non-mutated and
BRCA1-mutated breast cancer and their adjacent normal breast
tissues.
Additional file 2: Comparative analysis of histone modification and
E2F1 enrichment around the E2F1 motif between non-BRCA1-
mutated breast cancer and their adjacent normal breast tissues.
Additional file 3: Correlation between the H3K9ac or E2F1
enrichment, and +182 site methylation or DNMT1 expression in
BRCA1-mutated breast cancer and their adjacent normal breast
tissues.
Additional file 4: H3K9ac or E2F1 enrichment after silencing or
overexpression of BRCA1 in 293 T cells, and primary non-mutated
and BRCA1-mutated breast cancer and their normal breast cells.
Additional file 5: Compared of global DNA methylation levels
between BRCA1-mutated breast cancer and their adjacent normal
breast tissues.
Additional file 6: Knowdown effiency for the double-knockdown
and triple-knockdown in BRCA1-mutated breast cancer cells.
Additional file 7: Primers used in this study.
Additional file 8: List of commercial antibodies.
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